Intel stock extends gains after report of possible U.S. government stake
Investing.com - BTIG raised its price target on Liquidia Technologies (NASDAQ:LQDA) to $49.00 from $40.00 on Wednesday, maintaining a Buy rating on the stock. The company’s shares have shown remarkable momentum, gaining over 80% in the past year and trading near their 52-week high of $24.83. According to InvestingPro data, the stock currently appears overvalued based on its Fair Value analysis.
The research firm cited stronger-than-expected patient adoption of YUTREPIA, with 550 patients using the treatment as of August 8 and over 900 unique prescriptions written. This performance has already exceeded BTIG’s previous expectations for patient numbers that weren’t anticipated until late 2025 or early 2026. InvestingPro subscribers have access to 15+ additional exclusive insights about Liquidia’s growth prospects and financial health metrics.
BTIG has significantly increased its revenue projections for YUTREPIA, raising fiscal year 2025 estimates to $76.4 million from $26.5 million and fiscal year 2026 estimates to $601.9 million from $215.9 million. The firm assumes 50 new patients per week through year-end 2025 and an annualized net price of $225,000 per patient.
Liquidia ended the second quarter of 2025 with $173.4 million in cash and equivalents, which management indicates is sufficient to achieve profitability. The company is guiding toward profitability within three to four quarters. The company maintains a healthy current ratio of 2.93 and operates with moderate debt levels, though analysts don’t expect profitability in the current year.
Post-trial briefings for the Hatch Waxman trial between United Therapeutics and Liquidia have completed, with a final verdict expected in the second half of 2025. Liquidia also plans to host an R&D Day in the fall to provide updates on its L606 program.
In other recent news, Liquidia Technologies reported its second-quarter earnings for 2025, showing a substantial revenue increase. The company achieved $8.8 million in revenue, significantly exceeding the forecast of $3.92 million, largely due to strong sales of its Eutropia product. Despite a larger-than-expected loss per share of $0.49 compared to the anticipated $0.42, the market responded positively. Raymond James raised its price target for Liquidia to $41 from $33, maintaining a Strong Buy rating, citing a positive outlook for Yutrepia’s launch in PAH and PH-ILD. Wells Fargo also increased its price target to $31 from $25, keeping an Overweight rating, following a strong product launch performance. The company reported 94 unique patient prescriptions and 57 patient starts per week, surpassing analyst expectations. These developments indicate a robust performance for Liquidia Technologies in recent months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.